PTC Therapeutics (NASDAQ: PTCT) reported Q1 EPS of ($1.20), $0.09 better than the analyst estimate of ($1.29). Revenue for the quarter came in at $210.12 million versus the consensus estimate of $165.77 million.

GUIDANCE:

PTC Therapeutics sees FY2024 revenue of $600-680 million, versus the consensus of $606.6 million.

PTC anticipates GAAP R&D and SG&A expense for full year 2024 to be between $740 and $835 million.
PTC anticipates Non-GAAP R&D and SG&A expense for full year 2024 to be between $660 and $755 million, including expected R&D expense milestone payments of up to $65 million and excluding estimated non-cash, stock-based compensation expense of $80 million.
PTC anticipates up to $90 million of payments for full year 2024 upon achievement of potential regulatory success-based milestones from previous acquisitions, of which up to $65 million will be recorded as R&D operating expense.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.